tiprankstipranks
Trending News
More News >

Thiogenesis Advances Leigh Syndrome Treatment Trial

Story Highlights
Thiogenesis Advances Leigh Syndrome Treatment Trial

Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.

Confident Investing Starts Here:

Thiogenesis Therapeutics Corp., a biotech firm specializing in developing treatments for unmet pediatric diseases, has inked a research agreement with a leading U.S. pediatric hospital to assess its lead compound, TTI-0102, for Leigh syndrome – a rare, life-threatening genetic disorder. TTI-0102 aims to combat mitochondrial oxidative stress in Leigh syndrome by increasing antioxidant levels, potentially improving the condition. The company is preparing for a Phase 2a clinical trial following an anticipated pre-IND meeting with the FDA.

For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1